Cargando…

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whitfield, Thomas, Torkington, Adele, van Halsema, Clare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074732/ https://www.ncbi.nlm.nih.gov/pubmed/27799824 http://dx.doi.org/10.2147/HIV.S97920

Ejemplares similares

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Cabotegravir
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
por: Smith, Jennifer A, et al.
Publicado: (2020)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
por: Hill, Lucas, et al.
Publicado: (2018)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
por: Zhou, Tian, et al.
Publicado: (2017)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
por: Ebstie, Yehenew A, et al.
Publicado: (2016)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
por: Marzinke, Mark A., et al.
Publicado: (2023)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
por: Smith, Steven J., et al.
Publicado: (2018)

Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir
por: Patel, Parul, et al.
Publicado: (2018)

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso, Lily, et al.
Publicado: (2018)

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
por: Delany-Moretlwe, Sinead, et al.
Publicado: (2022)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
por: Parker, Ben, et al.
Publicado: (2021)

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
por: Lou, Yu, et al.
Publicado: (2016)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir
por: Han, Yanqiang, et al.
Publicado: (2021)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i8jpt17uuv37c9rdov6t9d96bl